Literature DB >> 14624175

Chemotherapy-induced secondary malignancies.

Teri Vega-Stromberg1.   

Abstract

Changes in chemotherapy protocols have influenced the risk and rate of secondary malignancies in high-risk populations. The alkylating agents, topoisomerase inhibitors, and anthracycline agents pose the highest risk of initiating carcinogenesis. Normal cells that are especially sensitive to chemotherapy and most likely to begin carcinogenesis include those of the bone marrow, hair follicles, and the epithelial cells of the gastrointestinal tract. Thus, the development of secondary hematologic cancers such as leukemia and lymphoma pose the greatest risk to adult and childhood cancer survivors. Lifelong surveillance is recommended.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624175     DOI: 10.1097/00129804-200311000-00004

Source DB:  PubMed          Journal:  J Infus Nurs        ISSN: 1533-1458


  13 in total

1.  Foe turned friend: multiple functional roles attributable to hyper-activating stem cell factor receptor mutant in regeneration of the haematopoietic cell compartment.

Authors:  S Pati; O P Kalra; A Mukhopadhyay
Journal:  Cell Prolif       Date:  2011-02       Impact factor: 6.831

Review 2.  Proteomic Research on the Antitumor Properties of Medicinal Mushrooms.

Authors:  Boris Jakopovic; Nada Oršolić; Ivan Jakopovich
Journal:  Molecules       Date:  2021-11-05       Impact factor: 4.411

3.  Second primary cancers in long-term survivors of glioblastoma.

Authors:  Jung-Young Kim; Jennifer G Jackman; Sarah Woodring; Frances McSherry; James E Herndon; Annick Desjardins; Henry S Friedman; Katherine B Peters
Journal:  Neurooncol Pract       Date:  2019-02-04

4.  Myc-driven overgrowth requires unfolded protein response-mediated induction of autophagy and antioxidant responses in Drosophila melanogaster.

Authors:  Péter Nagy; Agnes Varga; Karolina Pircs; Krisztina Hegedűs; Gábor Juhász
Journal:  PLoS Genet       Date:  2013-08-08       Impact factor: 5.917

5.  Lung cancer induced from chemotherapy a 20 years old case.

Authors:  Konstantinos Sapalidis; Stella Laskou; Aikaterini Amaniti; Stylianos Mantalovas; Dimitris Giannakidis; Charilaos Koulouris; Ilias Karapantzos; Chrysa Karapantzou; Konstantina Mponiou; Theodora Tsiouda; Fotis Konstantinou; Ioanna Kougioumtzi; Nikos Katsikogiannis; Chrysa Sardeli; Apostolos Gogakos; Nikos Schizas; Philip Domeyer; Paul Zarogoulidis; Isaak Kesisoglou
Journal:  Respir Med Case Rep       Date:  2018-03-27

6.  The relative risk of second primary cancers in Austria's western states: a retrospective cohort study.

Authors:  Oliver Preyer; Nicole Concin; Andreas Obermair; Hans Concin; Hanno Ulmer; Willi Oberaigner
Journal:  BMC Cancer       Date:  2017-10-24       Impact factor: 4.430

Review 7.  Tumor Profiling at the Service of Cancer Therapy.

Authors:  Ceres Fernandez-Rozadilla; Ana Rita Simões; Matilde E Lleonart; Amancio Carnero; Ángel Carracedo
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

8.  Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.

Authors:  Hyery Kim; Hyoung Jin Kang; Kyung Duk Park; Kyung-Nam Koh; Ho Joon Im; Jong Jin Seo; Jae Wook Lee; Nack-Gyun Chung; Bin Cho; Hack Ki Kim; Jae Min Lee; Jeong Ok Hah; Jun Ah Lee; Young Ho Lee; Sang Kyu Park; Hee Jo Baek; Hoon Kook; Ji Yoon Kim; Heung Sik Kim; Hwang Min Kim; Hee Won Chueh; Meerim Park; Hoi Soo Yoon; Mee Jeong Lee; Hyoung Soo Choi; Hyo Seop Ahn; Yoshifumi Kawano; Ji Won Park; Seokyung Hahn; Hee Young Shin
Journal:  Cancer Res Treat       Date:  2018-05-14       Impact factor: 4.679

9.  Nanoparticles as Tools to Target Redox Homeostasis in Cancer Cells.

Authors:  Francesco Ciccarese; Vittoria Raimondi; Evgeniya Sharova; Micol Silic-Benussi; Vincenzo Ciminale
Journal:  Antioxidants (Basel)       Date:  2020-03-04

Review 10.  Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma.

Authors:  Ayesha Atiq; Ishwar Parhar
Journal:  Molecules       Date:  2020-10-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.